Duopharma Biotech Berhad (KLSE:DPHARMA)
1.260
+0.030 (2.44%)
At close: Feb 21, 2025
Duopharma Biotech Berhad Balance Sheet
Financials in millions MYR. Fiscal year is January - December.
Millions MYR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
Cash & Equivalents | 264.55 | 270.5 | 157.64 | 137.98 | 158.03 | Upgrade
|
Cash & Short-Term Investments | 264.55 | 270.5 | 157.64 | 137.98 | 158.03 | Upgrade
|
Cash Growth | -2.20% | 71.60% | 14.25% | -12.69% | 30.96% | Upgrade
|
Accounts Receivable | 195.77 | 135.04 | 131.31 | 122.42 | 112.99 | Upgrade
|
Other Receivables | 18.19 | 26.38 | 10.84 | 10.31 | 22.18 | Upgrade
|
Receivables | 213.96 | 161.42 | 142.15 | 132.72 | 135.17 | Upgrade
|
Inventory | 248.55 | 243.07 | 235.18 | 222.19 | 151.27 | Upgrade
|
Prepaid Expenses | - | 2.08 | 6.52 | 1.9 | 0.67 | Upgrade
|
Other Current Assets | - | - | - | - | 14.56 | Upgrade
|
Total Current Assets | 727.05 | 677.07 | 541.49 | 494.8 | 459.69 | Upgrade
|
Property, Plant & Equipment | 566.29 | 582.37 | 579.92 | 542.53 | 441.79 | Upgrade
|
Long-Term Investments | 22.67 | 36.91 | 42.15 | 73.54 | 112.25 | Upgrade
|
Other Intangible Assets | 44.98 | 7.65 | 3.84 | 4.95 | 4.66 | Upgrade
|
Long-Term Deferred Tax Assets | 14.97 | 8.95 | 13.33 | 12.7 | 8.54 | Upgrade
|
Long-Term Deferred Charges | - | 31.15 | 40.14 | 34.58 | 30.41 | Upgrade
|
Other Long-Term Assets | 1.05 | 1.05 | 1.05 | 1.05 | 1.1 | Upgrade
|
Total Assets | 1,377 | 1,345 | 1,222 | 1,164 | 1,058 | Upgrade
|
Accounts Payable | 128.7 | 44.53 | 51.93 | 31.32 | 28.15 | Upgrade
|
Accrued Expenses | - | 33.79 | 40.46 | 61.2 | 45.62 | Upgrade
|
Short-Term Debt | - | 50.59 | 101.8 | 87.85 | 36.11 | Upgrade
|
Current Portion of Long-Term Debt | 48 | 14.95 | 32.34 | 15.08 | 12.68 | Upgrade
|
Current Portion of Leases | - | 0.92 | 0.94 | 0.64 | 0.6 | Upgrade
|
Current Income Taxes Payable | 0.74 | 0.37 | 1.17 | 6.06 | 0.74 | Upgrade
|
Other Current Liabilities | - | 21.58 | 35.95 | 28.17 | 26.41 | Upgrade
|
Total Current Liabilities | 177.43 | 166.73 | 264.59 | 230.31 | 150.32 | Upgrade
|
Long-Term Debt | 464.52 | 480.9 | 294.6 | 297.8 | 253.28 | Upgrade
|
Long-Term Leases | 2.83 | 1.48 | 1.92 | 2.48 | 0.66 | Upgrade
|
Long-Term Deferred Tax Liabilities | 23.06 | 8.91 | 5.58 | 9.54 | 10.35 | Upgrade
|
Total Liabilities | 667.85 | 658.01 | 566.7 | 540.13 | 414.61 | Upgrade
|
Common Stock | 432.47 | 432.47 | 419.37 | 405.86 | 404.92 | Upgrade
|
Retained Earnings | 354.78 | 319.07 | 288.37 | 239.97 | 220.18 | Upgrade
|
Comprehensive Income & Other | -78.09 | -64.41 | -52.52 | -21.82 | 18.72 | Upgrade
|
Shareholders' Equity | 709.15 | 687.12 | 655.22 | 624 | 643.82 | Upgrade
|
Total Liabilities & Equity | 1,377 | 1,345 | 1,222 | 1,164 | 1,058 | Upgrade
|
Total Debt | 515.35 | 548.85 | 431.6 | 403.84 | 303.33 | Upgrade
|
Net Cash (Debt) | -250.81 | -278.35 | -273.97 | -265.86 | -145.31 | Upgrade
|
Net Cash Per Share | -0.26 | -0.29 | -0.29 | -0.29 | -0.16 | Upgrade
|
Filing Date Shares Outstanding | 961.94 | 961.94 | 952.24 | 941.77 | 941.37 | Upgrade
|
Total Common Shares Outstanding | 961.94 | 961.94 | 952.24 | 941.77 | 941.37 | Upgrade
|
Working Capital | 549.62 | 510.34 | 276.9 | 264.49 | 309.37 | Upgrade
|
Book Value Per Share | 0.74 | 0.71 | 0.69 | 0.66 | 0.68 | Upgrade
|
Tangible Book Value | 664.18 | 679.47 | 651.38 | 619.06 | 639.16 | Upgrade
|
Tangible Book Value Per Share | 0.69 | 0.71 | 0.68 | 0.66 | 0.68 | Upgrade
|
Land | - | 65.68 | 69.88 | 69.88 | 69.88 | Upgrade
|
Buildings | - | 265.86 | 125.23 | 124.51 | 119.57 | Upgrade
|
Machinery | - | 435.18 | 368.47 | 308.94 | 291.64 | Upgrade
|
Construction In Progress | - | 8.48 | 172.65 | 162.63 | 65.81 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.